How Real-World Evidence Supports Healthcare Decisions in EU and Its Enlightment to China

摘要/Abstract

摘要： Objective To summarize the concept, background, application value of real-world evidence (RWE) and its enlightenment to China based on the analysis of the information about the RWE supporting health decision in the European Union, and to provide a reference for Chinese health departments. Methods Through literature research and data collection, the requirements of EU countries, especially some typical countries, for clinical evidence in health decision were obtained, and the application of RWE in supporting health decision in EU was analyzed with specific cases. Results and Conclusion RWE plays an increasingly important role in supplementing the evidence base of clinical trials, verifying the safety and effectiveness of medical devices, and accelerating the market access of new drugs. With the improvement of RWE quality, RWE will not only be used in the evaluation of biological agents and chemical drugs, but also play an important role in the evaluation of traditional Chinese medicine and the post-marketing evaluation of medical devices.

关键词: real-world evidence, EU, health decision, enlightment

Abstract: Objective To summarize the concept, background, application value of real-world evidence (RWE) and its enlightenment to China based on the analysis of the information about the RWE supporting health decision in the European Union, and to provide a reference for Chinese health departments. Methods Through literature research and data collection, the requirements of EU countries, especially some typical countries, for clinical evidence in health decision were obtained, and the application of RWE in supporting health decision in EU was analyzed with specific cases. Results and Conclusion RWE plays an increasingly important role in supplementing the evidence base of clinical trials, verifying the safety and effectiveness of medical devices, and accelerating the market access of new drugs. With the improvement of RWE quality, RWE will not only be used in the evaluation of biological agents and chemical drugs, but also play an important role in the evaluation of traditional Chinese medicine and the post-marketing evaluation of medical devices.

Key words: real-world evidence, EU, health decision, enlightment

Li Longxiao, Lian Guiyu. How Real-World Evidence Supports Healthcare Decisions in EU and Its Enlightment to China[J]. 亚洲社会药学, 2021, 16(3): 238-241.

Li Longxiao, Lian Guiyu. How Real-World Evidence Supports Healthcare Decisions in EU and Its Enlightment to China[J]. Asian Journal of Social Pharmacy, 2021, 16(3): 238-241.

[1]	Yang Lingling, Xu Fengxiang. EU Real-World Evidence Supports New Drug Research and Development Decisions and Its Implications for China[J]. 亚洲社会药学, 2021, 16(3): 197-202.
[2]	Lan Yipeng, Huang Zhe. Real-World Evidence Supporting New Drug Review and Approval in European Union and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(3): 203-208.
[3]	Yu Zhongyi, Xu Fengxiang. The Enlightenment of EU Real-World Evidence Supporting the Inclusion of Rare Disease Drugs in Medical Insurance Decisions to China[J]. 亚洲社会药学, 2021, 16(3): 209-213.
[4]	Wang JiaoJiao, Huang Zhe. EU Real-World Evidence Supports the Expansion Indications for Drugs and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(3): 214-218.
[5]	Wang Chao, Lian Guiyu. Research on Real-World Evidence and Application in EU and Its Enlightment to China[J]. 亚洲社会药学, 2021, 16(3): 219-224.
[6]	Yu Xiuna, Li Wanying, Dong Li. The Enlightenment of FDA’s “Real-World Evidence Program Framework” to China[J]. 亚洲社会药学, 2021, 16(3): 225-229.
[7]	Huang Xianqin, Chen Chuhan, Dong Li. Application of Real-World Evidence in Regulatory Decision-Making for Medical Devices[J]. 亚洲社会药学, 2021, 16(3): 230-237.
[8]	Fu Min, Huang Zhe, Xu Fengxiang. EU Real-World Evidence Supporting Drug Regulatory Decision and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(2): 103-107.
[9]	Yuan Hongmei, Zhang Wenfeng, Ma Junhong, Zeng Yingying, Meng Lingquan. Research on the Identification of Core Technologies of China’s Pharmaceutical Cold Chain Based on Patent Analysis[J]. 亚洲社会药学, 2021, 16(2): 128-138.
[10]	Ma Junhong, Zhang Wenfeng, Liu Yue, Yuan Hongmei, Zhang Dawei. Research on the Status Quo and Countermeasures of Patent Application in Liaoning Biopharmaceutical Industry Based on Patent Map[J]. 亚洲社会药学, 2021, 16(2): 145-153.
[11]	Li Meng, Huang Zhe. Empirical Analysis on Performance Evaluation of A Pharmaceutical Company Based on Economic Value Added[J]. 亚洲社会药学, 2021, 16(2): 154-162.
[12]	Yang Yu, Shi Yu, Hu Rongbo, Tian Lijuan. Research and Enlightenment of EU Drug Risk Management Plan[J]. 亚洲社会药学, 2021, 16(1): 23-30.
[13]	Qiao Jiahui, Wang Su, Chen Yuwen. Research on the Relationship between Export Orientation and R&D Investment of China’s Pharmaceutical Industry in Different Regions[J]. 亚洲社会药学, 2021, 16(1): 48-59.
[14]	Bu Hemeng, Xue Aoming, Zhang Fang. Literature Review on the Development of New Drugs Based on TRIZ[J]. 亚洲社会药学, 2021, 16(1): 60-67.
[15]	Cai Hongning, Sun Lihua. Research on the Construction of Pharmacy Organization and the Development of Pharmaceutical Services in China’s Primary Medical and Health Institutions— Based on the Survey of 5 Provinces [J]. 亚洲社会药学, 2021, 16(1): 93-101.

亚洲社会药学